Phase I trial of MS-275, a histone deacetylase inhibitor, administered weekly in refractory solid tumors and lymphoid malignancies

Shivaani Kummar*, Martin Gutierrez, Erin R. Gardner, Erin Donovan, Kyunghwa Hwang, Joo Chung Eun, Min Jung Lee, Kim Maynard, Mikhail Kalnitskiy, Alice Chen, Giovanni Melillo, Qin C. Ryan, Barbara Conley, William D. Figg, Jane B. Trepel, James Zwiebel, James H. Doroshow, Anthony J. Murgo

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

116 Scopus citations

Fingerprint

Dive into the research topics of 'Phase I trial of MS-275, a histone deacetylase inhibitor, administered weekly in refractory solid tumors and lymphoid malignancies'. Together they form a unique fingerprint.

Medicine & Life Sciences